Valuation Metrics and Recent Changes
As of early July 2026, Alkem Laboratories trades at ₹5,570.70, up 1.36% from the previous close of ₹5,495.95. The stock has fluctuated between a 52-week low of ₹4,716.75 and a high of ₹5,933.00, indicating a relatively stable price range over the past year. However, the company’s valuation grade has shifted from attractive to fair, signalling a moderation in price appeal.
The current P/E ratio stands at 27.58, a level that is higher than several key peers such as Zydus Lifesciences (21.08) and Lupin (19.64), both rated as attractive. This elevated P/E suggests that investors are paying a premium for Alkem’s earnings compared to these competitors. The price-to-book value ratio of 4.82 further supports this view, indicating a relatively rich valuation compared to the sector average.
Other valuation multiples include an EV/EBITDA of 22.03 and an EV/EBIT of 25.23, both of which are considerably higher than those of Zydus Lifesciences (14.17 EV/EBITDA) and Lupin (12.55 EV/EBITDA). These figures imply that Alkem’s enterprise value is priced at a premium relative to its earnings before interest, taxes, depreciation, and amortisation, reflecting market expectations of sustained profitability and growth.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Comparative Analysis with Peers
When benchmarked against its pharmaceutical peers, Alkem’s valuation appears less compelling. Zydus Lifesciences, Lupin, Biocon, and Glenmark Pharma all maintain attractive valuation grades with P/E ratios ranging from 19.64 to 22.08 and EV/EBITDA multiples significantly lower than Alkem’s 22.03. Notably, Mankind Pharma and Abbott India are classified as expensive, with P/E ratios of 51.77 and 35.39 respectively, suggesting that Alkem sits in a mid-range valuation band within the sector.
Alkem’s PEG ratio of 2.39 also indicates a higher price relative to earnings growth compared to Lupin’s 0.26 and Zydus Lifesciences’ 1.31, signalling that the market may be pricing in more optimistic growth expectations. However, this elevated PEG ratio warrants caution as it implies a stretched valuation relative to growth prospects.
Financial Performance and Returns
Alkem Laboratories’ return metrics over various time horizons highlight its relative outperformance against the Sensex. The stock has delivered a 1-year return of 15.57%, significantly outperforming the Sensex’s negative 6.58% over the same period. Over five and ten years, Alkem’s returns have been robust at 74.91% and 307.78% respectively, compared to the Sensex’s 48.16% and 186.48%. This strong historical performance underpins the premium valuation but also raises questions about sustainability amid rising multiples.
Operationally, Alkem maintains solid profitability with a return on capital employed (ROCE) of 19.58% and return on equity (ROE) of 17.48%, reflecting efficient capital utilisation and shareholder value creation. The dividend yield remains modest at 0.92%, consistent with a growth-oriented pharmaceutical company reinvesting earnings for expansion.
Market Sentiment and Grade Upgrade
MarketsMojo recently upgraded Alkem Laboratories’ Mojo Grade from Sell to Hold on 30 June 2026, reflecting improved investor sentiment and a stabilising outlook. The Mojo Score of 54.0 positions the stock as a mid-cap with moderate risk and reward characteristics. This upgrade suggests that while valuation remains fair rather than attractive, the company’s fundamentals and market positioning justify a neutral stance rather than a sell recommendation.
Why settle for Alkem Laboratories Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology mid-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Valuation Outlook and Investor Considerations
Investors analysing Alkem Laboratories must weigh the company’s premium valuation against its strong historical returns and solid operational metrics. The shift from an attractive to a fair valuation grade signals that the stock’s price appreciation has somewhat outpaced earnings growth, making it less compelling on a pure value basis.
Comparatively, peers such as Lupin and Zydus Lifesciences offer more attractive valuations with lower P/E and EV/EBITDA multiples, potentially providing better entry points for value-conscious investors. Meanwhile, companies like Mankind Pharma and Laurus Labs remain expensive, underscoring the diverse valuation landscape within the pharmaceuticals sector.
Alkem’s PEG ratio above 2.0 suggests that investors are paying a premium for growth, which may be justified if the company continues to deliver robust earnings expansion. However, any deceleration in growth or adverse sector developments could pressure the stock’s valuation.
Given the mid-cap status and the recent Mojo Grade upgrade to Hold, a cautious approach is advisable. Investors should monitor upcoming quarterly results, regulatory developments, and sector trends to reassess valuation attractiveness and potential price catalysts.
Conclusion
Alkem Laboratories Ltd’s valuation adjustment from attractive to fair reflects a maturing market perception amid competitive pressures and elevated multiples. While the company’s strong returns and operational efficiency justify a Hold rating, the premium valuation relative to peers warrants careful scrutiny. Investors seeking exposure to the pharmaceuticals sector may consider balancing Alkem’s growth potential against more attractively valued alternatives within the industry.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
